Insmed vs Kiniksa Pharmaceuticals International
INSM and KNSA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How INSM and KNSA compare
Insmed is the larger company, worth 1.7 times as much as Kiniksa Pharmaceuticals International ($24.6B against $14.4B).
Insmed grew revenue faster over the last twelve months (240% versus 58.9% for Kiniksa Pharmaceuticals International).
Kiniksa Pharmaceuticals International keeps more of each dollar of sales as profit, with a net margin of 9.6% compared with −39.9% at Insmed.
Kiniksa Pharmaceuticals International scores higher on the StockData Score (14 against 8 for Insmed), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | INSM | KNSA |
|---|---|---|
| Size and price | ||
| Market cap | $24.6B | $14.4B |
| Share price | $112.58 | $92.24 |
| Change, 1 year | −32.6% | 147% |
| Change, 5 years | 237% | 526% |
| Beta (5Y) | 0.79 | 0.34 |
| Employees | 1,664 | 366 |
| StockData Score | ||
| Total score | 8 | 14 (better) |
| Valuation score | 0 | 0 |
| Growth score | 3 | 4 (better) |
| Performance score | 2 | 4 (better) |
| Health score | 3 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 95.1× |
| P/S | 16.2× (better) | 17.1× |
| P/B | 33.9× | 22.0× (better) |
| EV/EBITDA | – | 136× |
| P/FCF | – | 78.7× |
| FCF yield | −2.6% | 1.3% (better) |
| Fair value | $61.67 | $11.65 |
| Margin of safety | −82.5% (better) | −692% |
| Growth | ||
| Revenue growth (TTM) | 240% (better) | 58.9% |
| Revenue growth, 5Y average | 29.8% | – |
| Net income growth (TTM) | – | 1584% |
| EPS growth (TTM) | – | 2325% |
| Profitability | ||
| Gross margin | 84.4% | 89.8% (better) |
| Operating margin | −37.1% | 11.9% (better) |
| Net margin | −39.9% | 9.6% (better) |
| FCF margin | −41.3% | 21.7% (better) |
| Return on equity | −72.5% | 14.0% (better) |
| Return on invested capital | – | 44.9% |
| Financial health | ||
| Debt / equity | 0.76 (better) | 0.00 |
| Interest coverage | −6.9× | – |
| Current ratio | 2.86 | 3.90 (better) |
| Altman Z-score | 6.56 | 37.02 (better) |
| Piotroski F-score | 4 | 8 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 103% | 30.1% |
| Held by insiders | 0.88% | 4.7% |
| Insider net buying, 12 months | −$167M | −$44.8M (better) |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 6.4% | 2.5% |
Go deeper
- INSM stock overview
- INSM income statement
- INSM valuation and score
- KNSA stock overview
- KNSA income statement
- KNSA valuation and score
Other comparisons
- ALNY vs INSM
- ARWR vs KNSA
- BBIO vs INSM
- BBIO vs KNSA
- INSM vs IONS
- INSM vs JAZZ
- INSM vs MDGL
- INSM vs RPRX
- INSM vs UTHR
For information only, not investment advice. Check the source filings before relying on any figure.